ReleaseWire Connect

The Report will be Dispatched in 3 Working Days.

DelveInsights,Tau Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Tau Inhibitors. This report provides information on the therapeutic development based on the Tau Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Telomerase Activators-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Telomerase Activators. This report provides information on the therapeutic development based on the Telomerase Activators dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,TGF-Beta-1 Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TGF-Beta-1 Inhibitors. This report provides information on the therapeutic development based on the TGF-Beta-1 Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Toll-Like Receptor 2 (TLR-2) Agonists-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Toll-Like Receptor 2 (TLR-2) Agonists. This report provides information on the therapeutic development based on the Toll-Like Receptor 2 (TLR-2) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Tetrahydrofolate Dehydrogenase Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Tetrahydrofolate Dehydrogenase Inhibitors. This report provides information on the therapeutic development based on the Tetrahydrofolate Dehydrogenase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Topoisomerase Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Topoisomerase Inhibitors. This report provides information on the therapeutic development based on the Topoisomerase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists. This report provides information on the therapeutic development based on the TRAIL Receptor 1 (TRAIL-R1 or Death Receptor 4 or DR4) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Synaptosomal Associated Protein 25 (SNAP-25) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Synaptosomal Associated Protein 25 (SNAP-25) Inhibitors. This report provides information on the therapeutic development based on the Synaptosomal Associated Protein 25 (SNAP-25) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Thymidine Kinase (TK) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Thymidine Kinase (TK) Inhibitors. This report provides information on the therapeutic development based on the Thymidine Kinase (TK) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.